PMID- 35059243
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230519
IS  - 2190-1678 (Print)
IS  - 2190-1686 (Electronic)
IS  - 2190-1678 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Jan
TI  - The forgotten type 2 diabetes mellitus medicine: rosiglitazone.
PG  - 49-65
LID - 10.1007/s13340-021-00519-0 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a chronic disease prevalent in the world, and 
      it is also one of the overall factors leading to overall morbidity and mortality. 
      Throughout Asia, the proportion of people with T2DM and obesity has increased and 
      this growth rate shows no signs of slowing down. Thiazolidinediones (TZDs) can 
      specifically treat insulin resistance and improve metabolic syndrome, including 
      rosiglitazone, troglitazone and pioglitazone, which are peroxisome 
      proliferator-activated receptor (PPAR) agonists. These drugs have been shown to 
      have better therapeutic effect and glycemic control, but also accompanied by a 
      series of adverse reactions. Cardiovascular events are currently the most serious 
      adverse events of rosiglitazone, which cardiovascular toxicity is higher than 
      pioglitazone. Rosiglitazone has been restricted or even withdrawal from the 
      market in most countries owing to concerns about its cardiovascular safety, while 
      its beneficial effect on insulin resistance has been demonstrated. New data on 
      rosiglitazone-mediated heart failure, myocardial infarction and fractures provide 
      clinicians with prescriptions with fewer side effects to treat patients. Studies 
      have shown that rosiglitazone is the most effective treatment in TZDs (in vivo 
      study), not only hypoglycemic effect but with some additional effects, such as 
      anti-inflammatory and anti-cancer capabilities, retinopathy (animal models) and 
      ischemia-reperfusion injury protection effects, lipid regulation and blood 
      pressure reduction, etc. Although rosiglitazone shows the highest risk of 
      arrhythmia in diabetes management while has the capacity to reduce the risk of 
      atrial fibrillation.
CI  - (c) The Japan Diabetes Society 2021.
FAU - Xu, Bo
AU  - Xu B
AUID- ORCID: 0000-0003-0594-9103
AD  - College of Pharmacy, University of South China, No. 28, Changsheng West Road, 
      Zhengxiang District, Hengyang, 421001 Hunan China. GRID: grid.412017.1. ISNI: 
      0000 0001 0266 8918
FAU - Xing, Aoxiang
AU  - Xing A
AD  - College of Pharmacy, University of South China, No. 28, Changsheng West Road, 
      Zhengxiang District, Hengyang, 421001 Hunan China. GRID: grid.412017.1. ISNI: 
      0000 0001 0266 8918
FAU - Li, Shuwei
AU  - Li S
AD  - College of Pharmacy, University of South China, No. 28, Changsheng West Road, 
      Zhengxiang District, Hengyang, 421001 Hunan China. GRID: grid.412017.1. ISNI: 
      0000 0001 0266 8918
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210629
PL  - Japan
TA  - Diabetol Int
JT  - Diabetology international
JID - 101553224
PMC - PMC8733070
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Insulin resistance
OT  - PPAR-gamma agonist
OT  - Rosiglitazone
OT  - Thiazolidinedione
OT  - Type 2 diabetes mellitus
COIS- Conflict of interestAll authors declare that they have no conflicts of interest.
EDAT- 2022/01/22 06:00
MHDA- 2022/01/22 06:01
PMCR- 2022/06/29
CRDT- 2022/01/21 06:21
PHST- 2021/05/30 00:00 [received]
PHST- 2021/06/24 00:00 [accepted]
PHST- 2022/01/21 06:21 [entrez]
PHST- 2022/01/22 06:00 [pubmed]
PHST- 2022/01/22 06:01 [medline]
PHST- 2022/06/29 00:00 [pmc-release]
AID - 519 [pii]
AID - 10.1007/s13340-021-00519-0 [doi]
PST - epublish
SO  - Diabetol Int. 2021 Jun 29;13(1):49-65. doi: 10.1007/s13340-021-00519-0. 
      eCollection 2022 Jan.